Similar articles

• CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion.

  Falsetti L, Viticchi G, Tarquinio N, Silvestrini M, Capeci W, Balloni A, Catozzo V, Gentile A, Pellegrini F. Falsetti L, et al. J Cardiovasc Med (Hagerstown). 2014 Aug;15(8):636-41. doi: 10.2459/JCM.0000000000000139. J Cardiovasc Med (Hagerstown). 2014. PMID: 24978663
• Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation.

  Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, Karanikis P, Pappa E, Siogas K, Goudevenos JA. Korantzopoulos P, et al. Int J Cardiol. 2005 Jul 10;102(2):321-6. doi: 10.1016/j.ijcard.2004.12.041. Int J Cardiol. 2005. PMID: 15982504 Clinical Trial.
• Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion.

  Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, Santini M. Loricchio ML, et al. Am J Cardiol. 2007 May 15;99(10):1421-4. doi: 10.1016/j.amjcard.2006.12.074. Epub 2007 Apr 5. Am J Cardiol. 2007. PMID: 17493472
• The efficacy and tolerability of commonly used agents to prevent recurrence of atrial fibrillation after successful cardioversion.

  Gonna H, Gallagher MM. Gonna H, et al. Am J Cardiovasc Drugs. 2014 Aug;14(4):241-51. doi: 10.1007/s40256-014-0064-5. Am J Cardiovasc Drugs. 2014. PMID: 24604773 Review.
• Atrial fibrillation: what are the effects of drug therapy on the effectiveness and complications of electrical cardioversion?

  Sarubbi B, Ducceschi V, D'Andrea A, Liccardo B, Santangelo L, Iacono A. Sarubbi B, et al. Can J Cardiol. 1998 Oct;14(10):1267-73. Can J Cardiol. 1998. PMID: 9852940 Review.